case_images: PMC10534040_01
case_images: PMC10534040_02
case_images: PMC10534040_03
case_images: PMC10534040_04
case_images: PMC10534040_05
case_images: PMC10534040_06
case_images: PMC10534040_07
case_images: PMC10534040_08
case_images: PMC10534040_09
case_images: Squamous cell carcinoma. (A) Before treatment with cemiplimab. (B) After treatment with cemiplimab.
case_images: fmed-10-1248894-g0001.jpg
case_images: PMC10534040_09_fmed-10-1248894-g0001.jpg
case_images: F1
case_images: Upon new progression of the disease, also involving the peritoneum and lungs (Figure 1A), a third line of treatment with cemiplimab was initiated on 3 May 2019, achieving a partial response (Figure 1B).